Interferon alpha, either leukocyte derived or the recombinant form, and the DNA gyrase inhibitor coumermycin A1 both inhibited human immunodeficiency virus type 1 (HIV) replication in vitro. We have found that combinations of these two agents synergistically inhibited HIV replication in human peripheral blood leucocytes (PBl). Significant inhibition was detected when both virion-associated reverse transcriptase activity and p24 levels were used as markers of replication. Mathematical analysis of data using the procedure of Chou and Chou (1987) produced combination indices of less than 1.0 for most effect levels at several combination ratios. Synergy was also evident when the classical isobologram technique was used for data analysis. Synergistic drug interactions were observed at concentrations not associated with cytotoxicity or anti-proliferative effects, and were seen at concentrations achievable in vivo.
Introduction
The emergence of the acquired immunodeficiency syndrome (AIDS) has resulted in major efforts to itfentify compounds active against HIV, with the nucleoside analogue zidovudine (azidothymidine, AZT) accepted for clinical use (Yarchoan et al., 1986) , and the efficacy of dideoxyinosine and dideoxycytosine undergoing evaluation in clinical trials (Merigan et al., 1989; Yarchoan et al., 1990) . In an attempt to reduce the adverse side-effects associated with long-term therapy and limit the emergence of isolates resistant to drugs such as AZT (larder et al., 1989) , combination chemotherapy with compounds targeted at the viral reverse transcriptase or other sites in the viral life-cycle has become increasingly more important as a strategy to control HIV infection.
Several drug combinations exhibiting in vitro synergy against HIV have been reported, and include interferon alpha with AZT (Hartshorn et al., 1987b) , and interferon alpha with recombinant soluble CD4 (rsCD4) and AZT (Johnson et al., 1990) . The in vivo efficacy of these combinations is at present undergoing clinical trials (Kovacs et al., 1989; Krown et et., 1990) .
Interferon alpha has in vitro activity against HIV (Ho et al., 1985; Hartshorn et al., 1987a) by preventing release of the virus particles from the surface of persistently infected cells (laurence, 1990; Yasuda et al., 1990) . In acutely infected T-cells, interferon alpha inhibits virus transcription and morphogenesis (Bednarik et al., 1989; Smith et al., 1991) . In vivo it is effective in the treatment of AIDS-associated Kaposi's sarcoma (lane et al., 1988) , and may have a role in slowing progression of Hlv-associated disease in the early-stage of infection (lane et al., 1990) , or, in more advanced cases, when administered in combination with AZT (Kovacs et al., 1989; Krown et al., 1990; Fischl etal., 1991) .
Coumermycin A1 is an antibiotic produced by Streptomyces spp. (Berger et al., 1966) . It is an inhibitor of prokaryotic DNA gyrase and, to a lesser extent, eukaryotic topoisomerase /I (Vosberg, 1985) , and its in vitro activity against HIV has been reported (Baba et al., 1989; Tachedjian et al., 1990) . Although known not to act at the level of the HIV RT (Tachedjian et al., 1990) , it remains unclear whether the inhibitory activity of coumermycin A1 relates to its classical mode of action or involves an unrelated mechanism.
Since interferon alpha and coumermycin A1 have novel anti-HIV activities and are both available clinically, we decided to evaluate the interactions of coumermycin A1 with both leukocyte interferon (IFN-ale) and a recombinant interferon preparation (Roferon, reclFN alpha 2a) in HIV infected PBl. Our results demonstrate that both combinations act synergistically against HIV replication.
Results

Synergistic anti-HIV effects of coumermycln A 1 and
IFN-aLe
Combination experiments were performed using serially diluted, fixed-ratio combinations of coumermycin A1 and IFN-ale. Inhibition experiments with each drug alone were Having established that coumermycin A1 and IFN-aLe produced synergistic inhibition of HIV replication in PBL, we were interested in determining whether a similar interaction could be observed with coumermycin A1 and an alpha interferon preparation licensed for clinical use. Coumermycin A1 was tested in combination with reclFN at four fixed-ratio, serially-diluted drug concentrations in HIV-infected PBL (Table 2 ). Moderate synergy was observed when both RT and p24 data was analysed by the median-effect analysis method for coumermycin A1 and reclFN at ratios of 1 :3.2 and 1 :6.4, with CI values ranging from 0.51-0.85 for 50%, 70%, and 90% effect levels. At Figure 1 shows the effect of a combination of coumermycin A1 and IFN-aLe at a ratio of 1 :25.6 on HIV replication 6days post-infection. Treatment with either drug alone resulted in dose-dependent inhibition of HIV replication when virion-associated reverse transcriptase (RT) and p24 antigen levels were measured in the supernatant. When combined, the drugs produced a greater inhibition of virus replication than when tested individually. Analysis of RT and p24 data by the median-effect analysis method revealed moderate synergy in both cases, with CI values for 50%,70%, and 90% effect levels ranging from 0.43-0.70 (Table 1) . Similarly, CI values for coumermycin A1 and IFN-aLe at ratios of 1: 3.2, 1: 6.4, and 1: 12.8 indicated synergy at the same effect levels (Table 1) . Toxicity controls at the highest concentration of each drug alone, and their combinations, were included in each experiment. They revealed no toxicity or anti-proliferative effects when analysed using a trypan blue exclusion method (results not shown).
As shown in Fig. 2 , CI values obtained from p24 and RT data for 1 :25.6 and 1 :3.2 ratios, respectively, were less than 1.0 over a range of effect levels. Synergy could also be demonstrated using mutually exclusive and non-exclusive isobologram analysis. The result for the ratio 1 :25.6 (RTdata) is shown in Fig. 3 for the mutually exclusive case.
• performed at the same time as combination experiments.
To facilitate mathematical analysis of the combination data by the Chou and Chou program, coumermycin A1 and IFN-aLe concentrations were chosen to given an expected inhibition of replication ranging from 0-100% and drug combinations at fixed ratios were selected. This enabled analysis of the data at 50%, 70%, and 90% effect levels (or other levels of inhibition if required), and calculation of a combination index (CI) for each ratio tested. CI values of <1.0 indicated synergy, equal to 1.0 additivity, and >1.0 antagonism. Chou and Talalay (1984) . Fig. 3 .lsobologram analysis of coumermycin A1 and IFN-aLe (L-IFN) combinations at a ratio of 1 :25.6 In this experiment RT data was analysed for the mutually exclusive case using the Dose-Effect Analysis Program of Chou and Chou (1987) .
studies (Hartshorn et al., 1987a) , we did not observe complete inhibition of HIV replication by interferon alpha as measured by virus specific cytopathic effect, RT and p24 core antigen levels. The classical in vitro antiviral activity of interferon alpha is at the level of protein synthesis following activation of a protein kinase and upregulation of a single-strand specific RNase L (Laurence, 1990) . This mode of action does not appear to play a significant role in inhibition of HIV replication, since interferon alpha acts at a late stage of HIV morphogenesis, assembly and release (Yasuda et al., 1990; Smith et al., 1991) . Nevertheless, interferon alpha is effective in the treatment of Kaposi's sarcoma in HIVinfected patients (Lane et al., 1988) , and in combination with AZT elicits anti-tumour and antiviral responses ratios of 1 : 12.8 and 1 :25.6 (fable 2), CI values less than 1.0 were seen for the highest inhibitory levels (ED 7o and EDgo) , while CI values at the ED 50 level were slightly antagonistic.
The CI values for fractional inhibition levels ranging from 0.05-0.95 are shown in Fig. 2 for a coumermycin A1-: reclFN ratio of 1 :3.2. Values less than 1.0 were obtained over the whole range of effect levels, with synergy being greatest at the highest levels. Synergy was also indicated by isobologram analysis (results not shown).
Discussion
In this study we found that combinations of leukocyte or recombinant interferon alpha with coumermycin A1 synergistically inhibited HIVreplication in PBL at concentrations that were neither toxic nor anti-proliferative. Some variability in anti-HIV response was observed between experiments for both interferon alpha preparations (results not shown), an effect which could be explained by donor PBL variation (Hartshorn et al., 1987a) . The combination of coumermycin A1 and IFN-aLe showed synergy over a wider range of fixed ratios than coumermycin A1 and rec-IFN, where in the latter case antagonism was observed at effect levels less than 70% for ratios 1: 12.8 and 1 :25.6 The reason for this may be due to the mixture of human interferon alpha subtypes having greater intrinsic activity compared with rec-IFN.
Anti-proliferative effects on cell growth were observed at concentrations of interferon alpha (IFN-aLe and rec-IFN) greater than 120lU rnr'. This differs from previous reports, where concentrations of recombinant human interferon alpha up to 1024 units rnl" had no effect on proliferation (Ho et aI., 1985) . In agreement with previous ( Kovacs et aI., 1989) , although adverse side effects including neutropenia and hepatic dysfunction are observed. The antiviral efficacy of interferon alpha seems to correlate with the presence of an intact immune system (Lane et aI., 1988) . In addition to these immunomodulatory and anti-tumour activities, interferon alpha appears to have anti-HIV effects in patients with CD4 levels greater than 200 J.L1-1 and appears to slow progression of HIV disease in asymptomatic patients (Lane et al., 1990) . However the dose required to achieve antiviral levels is associated with influenza-like symptoms and granulocytopenia (Laneet al., 1990) . It might be possible to minimize these adverse effects while retaining antiviral efficacy by administering interferon alpha at a lower dose in combination with other anti-HIV drugs.
Coumermycin A1 is an antibiotic originally developed for the treatment of methicillin-resistant staphylococcal infections (Berger et al., 1966) . It is active against these organisms at minimum inhibitory concentrations around 0.001 J.Lg mr' (Kawaguchi et al.,1965) , and also shows activity against other Gram positive and negative microorganisms. Its activity against HIV replication in MT-2 and PBL cells was established when screening a series of eukaryotic topoisomerase type I, topoisomerase type II, and DNA gyrase inhibitors with the HIV covalently closed circular DNA (supercoiled, SC) as the proposed target (fachedjian et al., 1990) . The mechanism of action of coumermycin A1 in inhibiting HIV replication is yet to be established, but it probably involves a different target to that of interferon alpha. It does not act at the level of the HIV RT (fachedjian et sl., 1990) and because it does not inhibit the replication of HIV in chronically infected cells (H9/HTLVIIIB), appears not to act at a post-integration level (G. Tachedjian, unpublished data).
As well as investigating coumermycin A1 and interferon alpha combinations, we have also studied the effects of combined coumermycin A1 and zidovudine in PBL and MT-2 cells infected with HIV,and found that the interaction was additive (unpublished data). The fact that this combination Wasnot synergistic was unexpected since the drugs have different modes of action.
Both cournerrnycin A1 and interferon alpha are available for clinical use and the pharmacokinetics of both is established (Kaplan, 1970; Gutterman et aI., 1982) . Antiviral concentrations of coumermycin A1 can be achieved in serum by intravenous or oral administration, the half life being in the range of 15-46 h in the latter case. The slow elimination rate of coumermycin A1 may result in a potential for prolonged therapeutic effectiveness. Of interest, is its activity against Mycobacterium tuberculosis (Kawaguchi et aI., 1965) . Infection with this agent, with extrapulmonary manifestations, is common in AIDS patients and the use of coumermycin A1 may be of clinical benefit (Barnes et al., 1991) . In view of the development of AZT resistance, drug combination therapy is a worthwhile pursuit and the availability of interferon alpha and coumermycin A1 makes them of potential use in the treatment of individuals infected with HIV.
Materials and Experimental procedures
Cells PBL were obtained from HIV seronegative donors and prepared as previously described (Neate et al., 1987) . They were depleted of monocyte and macrophages by glass adherence, and stimulated with phytohaemaglutinin (PHA, 10 fL9 ml-1 ) for 2-3 days in RPMI medium containing RPMI-1640 (Gibco, Grand Island, NY, USA), 10% v/v heat inactivated fetal calf serum (Flow Laboratories), 29.2 fL9 rnr ' glutamine, 100 U mr" penicillin, 100 fL9 rnl:" streptomycin and 0.1% NaHC0 3 • For use in drug combination assays, cells were transferred to IL-2 medium [RPMI medium supplemented with 20U mr ' recombinant interleukin-2 (Boehringer Mannheim, Mannheim, Germany), 4fL9 mr" hydrocortisone and 2 fL9 mr ' polybrene].
Virus
HIV-1 strain 237288 was isolated from the peripheral blood mononuclear cells of an AIDS patient undergoing treatment at Fairfield Hospital (Tachedjian et al., 1990) . The isolate had undergone an initial passage in MT-2, followed by one further passage in PBL. Its titre as determined by end point dilution assay in PBL was 10 4 . 5 TCID 5 0 rnr". 
Measurement of HIV expression
Supernatant fluids were assayed for particle-associated RT activity using a microassay method as previously described (Neate et al., 1987) ; p24 core antigen was detected using an HIVAG-1 enzyme immunoassay kit (Abbott Laboratories, North Ryde, NSW, Australia) and quantitated from a standard curve.
Mathematical calculation of drug interactions
To enable the determination of synergistic or antagonistic drug interactions using the multiple drug effect analysis procedure of Chou and Talalay (1984) and by an isobologram technique, data was expressed as the fraction affected (fractional inhibition of RT or p24) relative to untreated control cultures. Both forms of analysis are available on the Dose-Effect Analysis Program of Chou and Chou (1987) . Briefly, multiple drug effect analysis involves plotting the results obtained for each drug alone, or when combined at multiple fixed-ratio drug concentrations, in the form of a dose-effect curve defined by the median-effect equation falfu = (C/Cm)m. Fa and fu are the fractions affected and unaffected, respectively, by the concentration C. Cm is the concentration required to produce the median effect (I.e. 50% effective dose), and m represents the sigmoidicity of the curve. If the slopes (m) of the dose-effect curves for each drug alone and in combination are parallel, the drugs are said to be mutally exclusive (similar mode of action). Conversely, a mutually non-exclusive case (different mode of action) is defined by parallel gradients for each drug alone, with the gradient for the drug combinations being nonInterferon alpha and coumermycin A 1 combination 187 parallel. A combination index (CI) can be calculated for either mutually exclusive or non-exclusive assumptions. CI values less than one indicate synergy, CI values greater than one represent antagonism and a CI equal to one indicates additivity. For the analysis of coumermycin A1 and interferon alpha using multiple drug effect analysis, the mutually non-exclusive case (drugs with different modes of action) was assumed and only data with high linear correlation coefficients (r >0.8) as determined by the median effect plot were used in the computer analysis.
